Press Releases
February 14, 2019
Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an…
January 29, 2019
Challenge pour la Qualité de vie du patient 2019 : l’appel à projets est ouvert !
January 7, 2019
Debiopharm Group regains the commercial rights to Trelstar® (Triptorelin pamoate) and looks for new partners in North America
October 11, 2018
Debiopharm International SA and the Paul Scherrer Institute announce a licensing agreement for the development of a novel targeted radiotherapeutic…
September 28, 2018
The Japanese Cancer Association and Debiopharm Group Announce Winners of the 2018 JCA-Mauvernay Award
July 24, 2018
Debiopharm Investment, BNP Paribas Développement, Bpifrance et Tikehau Capital accompagnent la croissance du groupe Carbonex